chimeric antigen-receptor

Oncology

CAR-NK cell therapies are frequently misunderstood, despite growing clinical and preclinical data supporting their potential.

News

Biogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.